SpringWorks Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD -165.43 M

SpringWorks Therapeutics, Inc. Operating Cash Flow is USD -165.43 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -31.04% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • SpringWorks Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -239.91 M, a 37.33% change year over year.
  • SpringWorks Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -174.69 M, a 12.37% change year over year.
  • SpringWorks Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -155.46 M, a 321.34% change year over year.
  • SpringWorks Therapeutics, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -36.90 M, a -34.89% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities